Vol. 3 No. 1 (2023)
Reimbursement Reviews

Maribavir (Livtencity)

decorative image

Published January 25, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses maribavir (Livtencity) 400 mg (2 tablets of 200 mg) twice daily resulting in a daily dose of 800 mg.
  • Indication: Treatment of adults with post-transplant cytomegalovirus (CMV) infection or disease who are refractory (with or without genotypic resistance) to one or more prior antiviral therapies.